- Home
- PNRG vs ZNTL Comparison
PNRG vs ZNTL Comparison
Compare PNRG & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PNRG | ZNTL |
|---|---|---|
| Founded | 1973 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 344.8M | 289.0M |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PNRG | ZNTL |
|---|---|---|
| Price | $215.91 | $3.15 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $160.00 | $6.60 |
| AVG Volume (30 Days) | 74.8K | ★ 850.2K |
| Earning Date | 04-16-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.03 |
| EPS | ★ 4.57 | N/A |
| Revenue | ★ $189,052,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18.18 | N/A |
| P/E Ratio | $46.70 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $126.40 | $1.21 |
| 52 Week High | $278.90 | $6.95 |
Technical Indicators
Market Signals| Indicator | PNRG | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 58.83 | 28.56 |
| Support Level | $202.23 | $2.09 |
| Resistance Level | $225.59 | $3.30 |
| Average True Range (ATR) | 7.78 | 0.20 |
| MACD | -1.06 | -0.04 |
| Stochastic Oscillator | 52.26 | 0.94 |
Price Performance
Historical ComparisonAbout PNRG PrimeEnergy Resources Corporation
PrimeEnergy Resources Corp is an independent oil and natural gas company that is engaged in acquiring, developing, and producing oil and natural gas. It owns producing and non-producing properties located in Texas and Oklahoma. The company's business activities include development and exploratory drilling and providing well servicing support operations for many of the onshore oil and gas wells through its subsidiaries. It is also active in the acquisition of producing oil and gas properties through joint ventures with industry partners.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.